Experimental evaluation shows weak immune response in mice immunized with DNA encoding PsSP42, suggesting need for stronger adjuvants.
In our study, although the expected protective response was not achieved by any of the recombinant plasmids, the NTC-PsSP42 platform induced a weak Th1-polarized immune response, which partially influenced the parasite load. Since the new generation of plasmids are worth evaluating owing to the lack of antibiotic resistance genes on the backbone, we recommend further assessment of NTC-PsSP42 potential adjuvnated with immunostimulatory sequences such as as CpG motifs or even in heterologous prime-boost regimens.
No takes yet. Share an insight, caveat, or question.
Jahednia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: